Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Support Development of AKIR001 for the Treatment of Solid Tumors

pr_newswire_finance · 2026-08-20 · Bullish AI sentiment

$ITM

Akiram Therapeutics, a Swedish clinical-stage biotech company specializing in molecular radiotherapy, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced a supply agreement for non-carrier-added (n.c.a.) Lutetium-177 (Lu-177 or...

Read the original at pr_newswire_finance ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.